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Available online 30 December 2015Earlier studies proved the success of using chemically functionalisedmulti-walled carbon nanotubes (f-MWNTs)
as nanocarriers to the brain. Little insight into the kinetics of brain distribution of f-MWNTs in vivo has been re-
ported. This study employed awide range of qualitative and quantitative techniqueswith the aimof shedding the
light on f-MWNT's brain distribution following intravenous injection. γ-Scintigraphy quantiﬁed the uptake of
studied radiolabelled f-MWNT in the whole brain parenchyma and capillaries while 3D-single photon emission
computed tomography/computed tomography imaging and autoradiography illustrated spatial distribution
within various brain regions. Raman andmultiphoton luminescence togetherwith transmission electronmicros-
copy conﬁrmed the presence of intact f-MWNT inmouse brain, in a label-freemanner. The results evidenced the
presence of f-MWNT in mice brain parenchyma, in addition to brain endothelium. Such information on the rate
and extent of regional and cellular brain distribution is needed before further implementation into neurological
therapeutics can be made.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Drug transfer to the brain is greatly limited at the blood–brain barri-
er (BBB) by highly restrictive tight junctions between capillary endothe-
lial cells [1]. Improvements in drug transport across the BBB have been
shown by directly altering the physicochemical properties of the drug,
or coupling drugs to a vector including peptides, antibodies or nanopar-
ticles (NPs) [2,3] which are transported across the BBB by endogenous
receptor- or adsorptive-mediated transcytotic pathways.
Delivery systems including liposomes [4], polymeric nanoparticles
[5–7], gold nanoparticles [8], and to a lesser extent, dendrimers [9,10],
have raised tremendous hope for the treatment of several central
nervous system (CNS)-related disorders [11,12]. The maturation of
nanotechnology applications in biomedicine means that NPs with high
drug payloads can be engineered to have physiochemical propertiess), khuloud.al-jamal@kcl.ac.uk
. This is an open access article underfavourable for brain uptake. Furthermore, they can be surface
functionalised with biological ligands to target or cross the BBB.
Carbon nanotubes (CNTs) are a rather new category of nanomaterials
and have received great attention in the biomedical ﬁeld [13,14]. We
have developed biocompatible chemically functionalised CNTs (f-CNTs)
[15,16] and investigated their ability as drug carriers, gene carriers or as
imaging agents in vivo [17–19]. We demonstrated that f-CNTs improve
the anti-apoptotic effect of Caspase-3 siRNA after focal stroke in rats
when the f-CNT:siCas 3 complex is injected cortically [20] and that
functionalisation is important for cell uptake [21]. We recently reported
the intrinsic ability of f-MWNT to trancytose across an in vitro BBB
co-culture model with preliminary evidence of accessing mice brain
following i.v. injection [22]. In another study, we compared the in vivo
biodistribution proﬁles of two series of functionalised multi-walled
CNTs (f-MWNTs) following tail vein injection in mice [23]. The “thin”
f-MWNT, conjugated to humanised IgG or fragment antigen binding
region (Fab′), exhibited higher brain afﬁnity compared to the other
f-MWNT conjugates in the study. The present study aims to understand
the rate and extent of passive f-MWNT's access to brain parenchyma,
using a panel of quantitative and qualitative techniques, ranging inthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ously showing highest brain uptake, was used as a prototype. Techniques
used include quantitative γ-scintigraphy, 3D-single photon emission
computed tomography/computed tomography (SPECT/CT) imaging and
autoradiography, which altogether provided quantitative, temporal and
spatial information of high sensitivity. Direct imaging of f-MWNT-Fab′
in brain tissue was carried out using Raman spectroscopy and multi-
photon luminescence microscopy, coupled with lifetime imaging, offer-
ing excellent spatial resolution. Transmission electron microscopy
(TEM) also revealed the presence of f-MWNT-Fab′ in brain parenchyma
at an ultra-structural scale.
2. Materials and methods
2.1. Materials
Reagents for CNT functionalisation and other chemicals were pur-
chased from Sigma-Aldrich or Acros Organics (UK) if not speciﬁed
below. The MWNTs were provided by Nanocyl (batch# 171119,
Belgium). MWNTs were produced by the catalytic carbon vapour depo-
sition process with above 95% purity. Antibody hCTM01 Fab′ against
human polymorphic epithelial mucin (MUC1) was obtained from UCB
Celltech (UK). The radioactive probe [111In]Cl3 was purchased from
Mallinckrodt Pharmaceuticals (The Netherlands) as an aqueous solu-
tion in 0.5 M HCl and used without further puriﬁcation. Instant thin
layer chromatography paper impregnated with silica gel (iTLC-SG)
was obtained from Agilent Technologies (UK). Calcium ﬂuoride (CaF2)
slides (0.5 mm thickness, 20 mm diameter) for Raman spectroscopy
were supplied by Crystran Ltd. (UK). Mini protease inhibitor cocktail
kits (Roche Diagnostics, USA) was used to prepare brain lysates for
BCA protein assay (Pierce BCA kit, Thermal Fisher Scientiﬁc, UK), West-
ern blotting andELISA assay (BDOptEIA™, Mouse TNF ELISA set, BDBio-
sciences, UK). 1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine
perchlorate (DiI) was purchased from Santa Cruz Biotechnology Inc.
(Germany). Minimum Essential Medium (MEM) containing 25 mM
HEPES for preparation of isolated brain capillaries was purchased from
Life Sciences (UK).
2.2. Synthesis of chemically functionalised MWNTs
The synthesis of chemically functionalised MWNTs has been de-
scribed previously [23]. In brief, carboxylated and shortened MWNTs
were prepared by oxidation using strong acids. Following 1,3-dipolar
cycloaddition and amidation reactions, MWNTs were functionalised
with diethylenetriaminepentaacetic (DTPA) dianhydride chelatingmol-
ecules for complexation of the nuclear imaging probe 111In and further
modiﬁed with a model humanised MUC1 antibody fragment antigen
binding region (Fab′).
2.3. Radiolabelling of f-MWNTs
The DTPA conjugated f-MWNT-Fab′ was radiolabelled with 111In as
described previously [23]. Brieﬂy, MWNT-Fab′-DTPA (0.5 mg/ml in 5%
dextrose) was dispersed by bath sonication and then buffered with an
equal volume of 0.2 M ammonium acetate solution (pH 5.5) containing
111InCl3 (30 MBq or 4 MBq per 100 μg [111In]MWNT-Fab′ for SPECT im-
aging or γ-counting respectively). Solutions were mixed thoroughly by
vortexing every 5 min for 30 min at room temperature. The reaction
was stopped by the addition of 0.1 M EDTA chelating solution (1/20,
v/v). 111InCl3 alone was also subjected to the same conditions as a con-
trol. The labelling efﬁciencywas analysed by TLC. [111In]MWNT-Fab′ so-
lutions were spotted onto TLC strips, developed in 0.1 M ammonium
acetate buffer containing 50 mM EDTA as a mobile phase and allowed
to dry before analysis. The auto-radioactivity of each strip was devel-
oped and counted quantitatively using a Cyclone phosphor detector
(Packard Biosciences). Excess unreacted 111In was removed bycentrifugation at 13,000 rpm for 30 min to pellet [111In]MWNT-Fab′,
with unreacted 111In remaining in the supernatant. The pellets were re-
suspended in 5%dextrose at 0.5mg/ml for injection. TLCwas carried out
prior to each injection to ensure the absence of free 111In in the solution.
The stability of radiolabelling was examined by incubating disper-
sion of [111In]MWNT-Fab′ with an equal volume of PBS or human
serum at 37 °C for 24 h. The results were also analysed by TLC.
2.4. Animals
All in vivo experiments were conducted under the authority of pro-
ject and personal licences granted by the UK Home Ofﬁce and the
UKCCCR Guidelines (1998). Female C57/Bl6 mice aged 6–8 weeks
were purchased from Harlan (UK) for all the experiments.
2.5. Organ biodistribution by γ-scintigraphy
To study the organ uptake including brain, C57/Bl6 mice were intra-
venously (i.v.) injected with 50 μg of [111In]MWNT-Fab′ (0.5 mg/ml in
PBS) via a tail vein. At 5 min, 30 min, 1 h, 4 h or 24 h after injection,
blood samples were collected from a tail vein, the body was perfused
with 40 ml heparinised saline (50 U/ml) through the left ventricle of
the heart to wash out MWNTs remaining in blood or loosely bound to
tissues and the brain and other major organs were rapidly excised.
Excised brain and other tissues were weighed and the radioactivity
was measured by γ-scintigraphy (LKB Wallac 1282 Compugamma,
PerkinElmer).
2.6. Analysis of the uptake in brain parenchyma and capillaries by capillary
depletion
To separate the brain capillaries from the brain parenchyma, the
capillary depletion method modiﬁed for mice [24,25] was performed.
After γ-counting, the whole brain was homogenised in ice-cold physio-
logical buffer (10mMHEPES inHBSS, pH 7.4) using a glass homogeniser
on ice. When brain tissues were homogenised with 10 strokes of the
pestle in the homogeniser, a dextran solution (M.W. 64–76 kDa, 26%)
was added for a further brief homogenisation step (3 strokes of the
pestle). The homogenates were centrifuged at 5400 ×g for 15 min at
4 °C. The supernatants containing the brain parenchyma and the pellets
containing the brain capillaries were separately collected, followed by
γ-counting of the radioactivity of each fraction. The weight of the
brain parenchyma was estimated as the weight of the whole brain, as
the weight of capillaries is minimum compared to parenchyma.
2.7. TNF-α assay by ELISA
Mice were i.v. injected with 50 μg of MWNT-Fab′-DTPA (0.5 mg/ml
in PBS) and the brains sampled at 24 h and 72 h after injection. Brain tis-
sues were kept frozen at −80 °C until further analyses. Brain tissues
were homogenised in ice-cold RIPA lysis buffer (150mMNaCl, 0.1% Tri-
ton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mMTris–HCl, pH 8)
containing protease inhibitor. Homogenates were centrifuged at
17,949 ×g for 30 min and the supernatants were collected to measure
the protein concentration and TNF-α levels using for BCA and ELISA
assays respectively. Both assays were carried out according to their
manufacturers' instruction.
2.8. The effect of dexamethasone pre-treatment on brain uptake
To investigate if there was MWNT-induced inﬂammation that may
have affected its brain uptake, mice received a pre-treatment of
dexamethasone (10 mg/kg, i.p.) and were then given an injection
of [111In]MWNT-Fab′ (50 μg, 0.5 mg/ml in PBS, i.v.), an hour later.
Dexamethasone was prepared in dimethyl sulfoxide at 50 mg/ml
and then diluted in saline for injection. At 1 h post [111In]MWNT-
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and brains were isolated for gamma counting.
2.9. Brain 3D SPECT/CT imaging
In vivo brain uptake of [111In]MWNT-Fab′ was also examined by 3D
whole body SPECT/CT imaging. Mice were anaesthetised by isoﬂurane
inhalation and i.v. injected with 50 μg of [111In]MWNT-Fab′ (0.5 mg/ml
in PBS). SPECT/CT scans were carried out at multiple time points on the
same animal, immediately post injection, at 4 h and 24 h in the prone po-
sition using the Nano-SPECT/CT scanner (Bioscan, USA). SPECT scanning
was acquired over 24 projections (60 s per projection), using a 4-head
scanner with 1.4 mm pinhole collimators, for a total acquisition time of
30–40 min. CT scans were performed using a 45 kVP X-ray source after
each SPECT. SPECT images were reconstructed using HiSPECT (Scivis
GmbH, Germany) and CT images were reconstructed using
InVivoScope™, proprietary Bioscan software. Both images were fused
and analysed by InVivoScope™.
2.10. Autoradiography
To investigate the regional distribution of f-MWNTs in the brain, [-
111In]MWNT-Fab′ (5–7 MBq, 50 μg, 0.5 mg/ml in PBS) was i.v. injected
in mice and the brains were isolated at 5 min, 4 h or 24 h after injection
for autoradiography. Studies using mice injected with [111In]EDTA con-
taining similar radioactivity (5–7 MBq) were also performed as a con-
trol for comparison. Each brain was cut into 2 mm thick coronal
sections using a mouse brain matrix (Zivic-Miller, USA). Sections were
placed between two glass microscope slides and these sandwich units
were in contact with super sensitive plates (Cyclone® storage phosphor
screen, Packard) for 18–20 h in autoradiography cassettes (Kodak
Biomax Cassette®) before scanning using cyclone phosphor detector
(Packard Biosciences).
2.11. Administration of f-MWNTs using in situ brain perfusion
[111In]MWNT-Fab′ was administered to mouse brains using the in
situ brain perfusion technique via cardiac perfusion [26]. This
protocol was carried out to maintain a steady blood concentration
of [111In]MWNT-Fab′ at all times and administer [111In]MWNT-Fab′
to brain directly via carotid and vertebral arteries rather than via intra-
venous injection, so avoiding ﬁrst pass effect of peripheral organs. Mice
wereweighed and anaesthetisedwith i.p. injection of a cocktail solution
of Domitor® (Orion Pharma, Finland) and Vetalar™ V (Pﬁzer, UK),
freshly mixed before injection. [111In]MWNT-Fab′ in PBS (0.5 mg/ml)
was added to the perfusion solution, a protein containingRinger's buffer
(117 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 24.8 mM
NaHCO3, 1.2 mM KH2PO4, 10 mM glucose, and 30 g/l bovine serum al-
bumin). During perfusion, pre-gassed (5% CO2 in O2) Ringer's buffer
containing [111In]MWNT-Fab′ (0.4 μg/ml) was maintained at 37 °C
using a water heater and passed through a ﬁlter and bubble trap before
reaching the left ventricle of the heart. Perfusion rate was kept constant
at 5 ml/min using a peristaltic pump. Mice were perfused for 5, 10 or
30 min followed by one minute perfusion without [111In]MWNT-Fab′
to wash out residual construct from the vasculature. At the end of
perfusion, different brain compartments (i.e. choroid plexus, brain
cortex, olfactory bulbs, cerebellum, thalamic region and brainstem)
were dissected and weighed, and the radioactivity from each sample
was measured by γ-scintigraphy (LKB Wallac 1282 Compugamma,
PerkinElmer, UK).
2.12. Histology studies
For histological examination, mice were i.v. injected with a dose of
MWNT-Fab′-DTPA at 200 μg/mouse (1 mg/ml in PBS). Considering the
obtained % ID in brain, a higher injection dose was given here, as wellas in the following Raman, multi-photon and TEM studies, to facilitate
the detection of MWNT-Fab′-DTPA microscopically. Brains were
harvested at 5min after cardiac perfusionwith 4% PFA for general histo-
logical examination. Samples were then wax-embedded and sectioned
for Nissl and Luxol Fast Blue or Neutral Red stains according to standard
histological protocols at the Royal Veterinary College, UK. Stained
sections were analysed using a Leica DM 1000 LED Microscope (Leica
Microsystems, UK) coupled with CCD digital camera (Qimaging, UK).
2.13. Ex vivo Raman spectroscopic analysis
Raman spectroscopy studies of MWNT-Fab′-DTPA in the mouse
brain were performed using an inVia™ Raman microscope (Renishaw,
UK). Spectra were acquired in the StreamLine™ scanning mode. Mice
were either i.v. injected with MWNT-Fab′-DTPA (200 μg, 1 mg/ml in
PBS) or saline (PBS) and the brainswere isolated at 5min after injection.
Both frozen brain sections and isolated brain capillaries were prepared
for Raman spectroscopy. For frozen sections, the entire brain was
snap-frozen and sectioned into 10 μm thick sections. For the isolated
brain capillaries, freshly isolated brains were homogenised in MEM
containing 25 mM HEPES. The homogenates were then ﬁltered using a
60 μm nylon mesh to separate the capillaries from the homogenates.
The capillaries were suspended in MEM and further concentrated by
centrifugation at 3220 g for 15 min. Capillaries or brain sections were
deposited on a calcium ﬂuoride slide and allowed to dry. MWNT-Fab′-
DTPA in DMF dispersion (50 μl, 20 μg/ml in DMF), deposited on a calci-
um ﬂuoride (CaF2) slide,was used as a reference. Sampleswere scanned
using a 785 nmHPNIR785diode laser (15mW, 10% laser power and 10 s
exposure) through a 60×/1.20 NA water objective. Raman signals were
acquired using a 300 lines/mm grating centred between 917.67 cm−1
and 2326.15 cm−1 and 10 s CCD exposure time. The spectral resolution
was 8.55 cm−1. For each sample, 3 regions (119 μm × 119 μm each)
were imaged and around 40,000 spectra per region were recorded.
Pearson-based cluster analysis of the data set was performed using an
in-house programme [27] designed to identify independent cluster
components in the sample.
2.14. Multi-photon luminescence and lifetime microscopy
Mice were i.v. injected with MWNT-Fab′-DTPA (200 μg, 1 mg/ml in
PBS). At 1 h after injection, mice were transcardially perfused consecu-
tively with PBS, DiI solution (0.12 mg/ml in PBS–5% glucose mixture)
and 4% PFA [28]. Brains were sectioned into 1 mm thick slices and
kept in 4% PFA in the dark at 4 °C until use. Brain slices were placed
onto microscope slides and covered with coverslips for microscopic im-
aging. Multi-photon luminescence images of MWNT-Fab′-DTPA and DiI
in brain were acquired with excitation at 950 nm (~140 fs pulse width,
80 MHz) using a tunable Coherent Chameleon II Ti:Sapphire IR laser
(Coherent, USA). Imaging was carried out using a confocal microscope
(A1R Si MP Confocal, Nikon, Japan) with a 40× water immersion
objective (Nikon, Japan) and ﬂuorescence signals were captured via
three bandpass ﬁlters (492 nm SP, 525/50 nm, and 575/25 nm
appearing in blue, green and red respectively). Fluorescence from DiI
and MWNT-Fab′-DTPA could be differentiated since DiI ﬂuorescence
wasmainly detected in the red channelwhileMWNT-Fab′-DTPA signals
were measured in all channels.
Lifetimemicroscopywas further carried out on the physically-mixed
dispersion of DiI and MWNT-Fab′-DTPA, as well as the brain slices from
the above two-photon microscopy studies. This imaging technique can
distinguish signals from DiI and MWNT-Fab′-DTPA with good resolu-
tion due to the distinct differences in their lifetimes. The DiI & MWNT-
Fab′-DTPA mixture was prepared by mixing equal volumes of DiI
(1 μg/ml in ethanol) and MWNT-Fab′-DTPA (1 mg/ml in H2O). A drop
of the mixture (20 μl) was deposited onto a microscope slide and
allowed to dry for imaging. An in-house multi-photon imaging system
built onto a Nikon Eclipse Ti inverted microscope (Nikon, Tokyo,
25J.T.-W. Wang et al. / Journal of Controlled Release 224 (2016) 22–32Japan)was employed. Sampleswere excited using a tunable Ti:sapphire
laser (~140 fs, 80 MHz, Coherent, USA) at 950 nm and no confocal
pinhole was used. Lifetime imaging and intensity data were acquired
using a Becker & Hickl HPM-100-40 high speed hybrid detector and a
SPC-150 TCSPC card (Becker & Hickl, Germany) via a 20×/0.75NA
Nikon objective lens. Lifetime data was analysed using an in-house
software.
2.15. Transmission electron microscopy studies
Mice were i.v. injected with MWNT-Fab′-DTPA (200 μg, 1 mg/ml in
PBS) and the brainswere isolated at 5min afterwhole body cardiac per-
fusion with freshly-prepared 50 ml of 2.5% glutaraldehyde solution in
0.1 M cacodylate buffer. The brains were immersed in the perfusate
for 24 h at 4 °C before taking 1 mm thick sections using a mouse brain
matrix (Zivic-Miller, USA). Sections were rinsed with 0.1 M cacodylate
buffer to remove excess glutaraldehyde and kept in 0.1 M cacodylate
buffer at 4 °C until use. The brain sectionswere stainedwith 1% osmium
tetroxide for 3 h, dehydrated with increasing concentrations of ethanol
from 70% to 100%, and then soaked with propylene oxide for 1 h to
facilitate the brain inﬁltration of embedding resin. Brain sections were
incubated with a solution of 1:1 propylene oxide: epoxy resin (43.7%
Araldite CY212, 54.5% DDSA and 1.7% DMP30) for 24 h at room temper-
ature with shaking. Finally, brain sections were embedded into epoxy
resin for 3 days at 60 °C, allowing the polymerisation process to occur.
Ultrathin sections (65 nm) were cut on a 45° diamond knife (DiATOME,
USA) from the blocks using a microtome (Leica Richert Ultracut) and
collected on copper 200-mesh grids. Some brain sections were further
stained with uranyl acetate (25% in methanol) for 3 min and 3% lead
citrate solution for 8 min to visualise cells with better image contrast
(Fig. S5).
TEM analysis was also carried out on brain capillaries extracts. The
brain capillaries from untreated mice and mice injected with MWNT-
Fab′ were isolated following the same procedures as described above.
The collected pellets containing brain capillaries were re-suspended in
2.5% glutaraldehyde solution in 0.1 M cacodylate buffer for ﬁxation
for 24 h at 4 °C. Samples were washed with 0.1 M cacodylate buffer
by centrifugation at 3220 g for 15 min and the pellets were re-
suspended in 50 μl of 1% molten agarose and allowed to solidify at
room temperature. The capillaries in agarose gel were stained with
1% osmium tetroxide for 3 h, processed as described above and
then imaged by TEM.
Bright ﬁeld TEM images of brain sections and isolated capillaries
were acquired using a Philips CM12 transmission electron microscope
(Phillips, The Netherlands) at 80 kV acceleration voltage, with 150 μm
objective aperture.
2.16. Statistical analysis
Quantitative results are expressed as mean ± S.D. (n = 3–4).
Statistical signiﬁcance was calculatedwith one-way ANOVA. Signiﬁcant
difference was established at p b 0.05.
3. Results and discussion
3.1. Synthesis, radiolabelling and stability studies
Chemical synthesis and detailed physiochemical characterisation of
the MWNT-Fab′-DTPA conjugate have been assessed previously
(Fig. S1) [23]. The results from several analyses such as Kaiser test, ther-
mogravimetric analysis, gel electrophoresis and surface plasma reso-
nance determined the antibody loading, assured the antibody activity
after conjugation and all conﬁrmed the success of functionalisation.
No structure changes before and after antibody conjugation were ob-
served using TEM [23]. The diameter and length of MWNT-Fab′ DTPA
were measured as 9.2 ± 2.7 nm and 396 ± 290, respectively, with theFab′ loading as 3 μmole of Fab′/g of CNT. The chemical structure of the
studied MWNT-Fab′-DTPA is shown in Fig. 1a and Fig. S1. MWNT-Fab′
functionalised with DTPA was radiolabelled with 111In to
yield [111In]MWNT-Fab′ and 49.4 ± 5.4% labelling efﬁciency was
achieved as assessed by TLC examination (Fig. S2). Non-chelated 111In
was removed by centrifugation. [111In]MWNT-Fab′ remained stable in
50% serum and PBS at 37 °C for 24 h. Negligible free 111In was detected
as shown by TLC (Fig. S2).
3.2. Quantitative brain uptake analyses by γ-scintigraphy
Mice were i.v. injected with [111In]MWNT-Fab′ to assess the brain
uptake proﬁles. The brain and other major organs were excised at mul-
tiple time points at 5 min, 30 min, 1 h, 4 h and 24 h for γ-scintigraphy.
Transcardial perfusion was performed before harvesting organs in
order to wash out f-MWNTs still present in the vascular compartment
at the time of sacriﬁce. Blood circulation proﬁles were also examined
by taking blood samples immediately before perfusion.
Fig. 1b illustrates the amount of [111In]MWNT-Fab′ in the brain and
blood over time, expressed as percentage of injected dose per gram of
brain or blood (% ID/g of organ). The brain accumulation was rapid,
and could be detected at the earliest time point assessed in this study
of 5 min post injection. Brain levels then decreased steadily up to 24 h,
in contrast to the relatively rapid drop in blood concentration observed
within the ﬁrst hour after injection. [111In]MWNT-Fab′ displayed ~5%
and 3% ID/g of brain at 5 min and 30 min post-injection (p.i.). At 1 h, a
signiﬁcantly higher brain uptake (2.2 ± 0.6%) compared to blood
(0.7 ± 0.1%) was detected (p ≤ 0.01). Capillary depletion [24,25]
employed to separate brain parenchyma from the capillaries (Fig. 1c),
revealed higher % ID detected in the capillary fraction compared to pa-
renchyma over the studied 24 h, suggesting the high afﬁnity of
[111In]MWNT-Fab′ to brain endothelium. Interestingly, [111In]MWNT-
Fab′ levels declined gradually in the capillary fractions, over the ﬁrst
hour, compared to the more sustained proﬁle observed in the brain pa-
renchyma. Fig. 1d compares the concentration in the blood versus brain
parenchyma over time. The brain parenchyma to blood ratio represents
the extent of brain penetration of [111In]MWNT-Fab′, i.e. the transloca-
tion from blood circulation, crossing brain capillaries, and reaching
parenchyma [29]. The highest brain parenchyma (% ID/g) to blood (%
ID/g) ratio obtained was 1.31 ± 0.52 at 1 h, which was signiﬁcantly
higher than the values measured at 4 h and 24 h.
The blood circulation and brain uptake of [111In]MWNTwithout Fab′
conjugation were also studied. The results in comparison with
[111In]MWNT-Fab′ are shown in Fig. S3. Similar blood proﬁles
with short blood circulation time were obtained for [111In]MWNT and
[111In]MWNT-Fab′ (Fig. S3a). However, as shown in Fig S3b,
signiﬁcantly lower brain accumulation was measured for [111In]MWNT
at earlier time point (i.e. 5 min and 30 min post injection) compared to
[111In]MWNT-Fab′ (p b 0.05). After capillary depletion, [111In]MWNT
also exhibited lower uptake in both brain parenchyma and capillaries
(Fig. S3c–d). As a result, lower brain parenchyma to blood ratios were
obtained for [111In]MWNT compared to [111In]MWNT-Fab′ over the
studied time course in which the highest ratio was measured as
0.14 ± 0.02 at 4 h post injection.
The introduction of any synthetic particle in the circulation raises
concerns about possible inﬂammation particularly since inﬂammation
can cause increased BBB permeability, thus resulting in high brain
uptake [30,31].We have reported previously that the f-CNTs undergone
similar functionalisation induced low levels of pro-inﬂammatory cyto-
kines with the observation of degradation at 48 h after stereotactic in-
jection [21,32]. In our recent work, no signiﬁcant toxicity was
measured in primary neurons isolated from different brain regions of
foetal rats after incubation with f-CNTs for 24 h [33]. Here we examined
brain levels of the pro-inﬂammatory cytokine TNF-α after MWNT-Fab′-
DTPA administration by enzyme-linked immunosorbent assay (ELISA).
The cytokine levels in brain increased at 24 h post-injection but
Fig. 1. Blood circulation and brain uptake of [111In]MWNT-Fab′ after i.v. injection at different time points by γ-scintigraphy. (a) The structure of chemically functionalised MWNT-Fab′-
DTPA; (b) % ID/g of whole brain and % ID/g of blood; (c) disposition of [111In]MWNT-Fab′ (% ID) in brain capillaries and parenchyma after capillary depletion; (d) brain parenchyma to
blood ratio calculated from the concentration of [111In]MWNT-Fab′ in brain parenchyma and blood (% ID/g). Mice were i.v. injected with 50 μg of [111In]MWNT-Fab′. Results are
expressed as mean ± S.D. (n = 4). Statistical analysis was performed using One-Way ANOVA (*p b 0.05; **p ≤ 0.01).
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Although TNF-α increased in brain with f-MWNT administration,
it was a modest increase and considerably lower than levels in an
inﬂammation model using LPS for example [34]. To further elimi-
nate brain inﬂammation as a causative factor for brain uptake of f-
MWNT, mice were pre-treated with dexamethasone (10 mg/kg,
i.p.), an anti-inﬂammatory drug, one hour prior to [111In]MWNT-
Fab′ injection. [111In]MWNT-Fab′ was then injected and the brainFig 2. In vivo SPECT/CT imaging ofmouse brains. (a) Sagittal, coronal and transverse views from
(50 μg, 5–7 MBq) at 0–30 min, 4 h and 24 h post injection; (b) dynamic SPECT/CT imaging of muptake was assessed at 1 h post-injection. This is the time point
where the highest brain parenchyma/blood ratio was achieved for
[111In]MWNT-Fab′ (Fig. 1d). No signiﬁcant difference in brain up-
take was detected with or without the pre-treatment of dexameth-
asone (p = 0.4, Fig. S4b). TEM images of brain also showed the
maintenance of brain capillaries after i.v. injection of MWNT-Fab′-
DTPA. As shown in Fig. S5, capillaries remained intact and were
seen in a smooth circular shape, not extruded, with tight junction3D reconstructed SPECT/CT images ofmouse brains after i.v. injection of [111In]MWNT-Fab′
ouse brain (sagittal views) within 100 min after injection of [111In]MWNT-Fab′.
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gether, these results indicate neither inﬂammation nor the damage
in BBB (BBB leakage) was induced by the introduction of MWNT-
Fab′-DTPA and they were not the reasons for the high brain
uptake of MWNT-Fab′-DTPA.
A targeting f-CNTs system was developed by Ren et al. for brain gli-
oma therapy [35]. MWNTs were incorporated with an anticancer drug
doxorubicin and polyethylene glycol, in which the polymer was conju-
gated with a brain targeting ligand Angiopep-2. This targeting system
demonstrated enhanced brain uptake of doxorubicin. This was con-
ﬁrmed by an indirect detection of doxorubicin ﬂuorescence signals
from the construct. In this regard, the present work performed a quan-
titative assessment of the distribution kinetics of the carrier in the brain.
The brain uptake values of ~2–5% ID/g reported in this study are consid-
erably higher compared to other types of targeted nanoparticles, which
range from 0.3% to 0.5% ID/g of brain [25,36–38]. More importantly, the
brain parenchyma to blood ratios of [111In]MWNT-Fab′ were in excess
of 0.2 between 30 min to 24 h post injection and peaked at 1.31 at 1 h.
It is noteworthy that many CNS drugs including morphine show good
CNS distribution with their brain to blood ratios N0.5 [39,40] and most
CNS drugs in the market can achieve only 0.2% of their peripheralFig. 3. Autoradiographs of mouse brain after i.v. injection of [111In]MWNT-Fab′ or [111In]EDTA
(50 μg) or (b) [111In]EDTA. Brains were harvested at 5 min, 4 h or 24 h after injection. In the
were sectioned in coronal orientation from olfactory bulbs to brainstem in 2 mm thick sectiondoses [30]. The studied MWNT-Fab′ clearly demonstrated superior
brain uptake and holds a great potential as a delivery vehicle for CNS
diseases. Taking into account the studied f-MWNT achieved 15–20%
antibody/Fab′ loading (μg of antibody/μg of CNT) [23], one can simply
assume that this payload can be replaced with the therapeutic
antibodies of choice.
The Fab′ used here is against human polymorphic epithelial mucin
(MUC1) which is not expressed in mouse brain (Fig. S6). Therefore,
the signiﬁcant brain uptake of [111In]MWNT-Fab′ is unlikely to be due
to the antibody targeting effect but can be attributed to the nanotube's
ability to penetrate endothelial/brain cells.
The biodistribution proﬁles of [111In]MWNT and [111In]MWNT-Fab′
in organs other than brain and blood are shown in Fig. S7. Both
[111In]MWNT and [111In]MWNT-Fab′ exhibited prominent uptake in
liver, lung and spleen, consistent with the results obtained in our
previous studies, conducted without transcardial perfusion [23].
3.3. 3D SPECT/CT imaging and autoradiography
The brain uptake of radiolabelled [111In]MWNT-Fab′ after i.v. injec-
tion was also conﬁrmed by SPECT/CT imaging. In line with the resultsat different time points. Mice were i.v. injected with 5–7 MBq of (a) [111In]MWNT-Fab′
case of [111In]EDTA, autoradiography was only performed at 5 min after injection. Brains
s (c1–c6).
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time points (0–4 h) while the radioactivity decreased at 24 h (Fig. 2a).
[111In]MWNT-Fab′ seemed to distribute over the entire brain but ap-
peared to be more concentrated in the midbrain region, seen most
clearly in the 4 h images (indicated by the cross hairs).
Dynamic SPECT/CT imaging of [111In]MWNT-Fab′ in the mouse
brain was further performed to monitor the distribution changes,
particularly at early time points after injection. Mice underwent 4
successive SPECT scanning with images acquired every 25 min for a
total of 100 min. Physiological shifting of the radioactivity in the
brain could be visualised over time shown in the sagittal views in
Fig. 2b. Heterogeneous distribution could be clearly observed using
this imaging method. Mice were also injected with the [111In]EDTA
radiolabel alone as controls and subjected to both γ-scintigraphy
and SPECT/CT imaging studies (Fig. S8). By SPECT/CT imaging, [-
111In]EDTA was mainly excluded from the brain cavity at 30 min
after injection and cleared from blood by 4 h (Fig. S8a). The amount
of [111In]EDTA measured in the brain was signiﬁcantly lower than
the values obtained for [111In]MWNT-Fab′ throughout the studied
time points (Fig. S8b). These results conﬁrmed that the radioactivity
detected in the brain after [111In]MWNT-Fab′ injection originated
from [111In]MWNT-Fab′ rather than free 111Inwhichmay have disso-
ciated from MWNT-Fab′-DTPA after injection.
Autoradiography of brain slices was also conducted to provide
greater spatial resolution (μm range), allow sensitivity improvement
by increasing the exposure time [29] and support semi-quantitative
analysis of particle accumulation in different brain regions. Fig. 3a
shows representative autoradiographs of [111In]MWNT-Fab′ from
coronal brain slices (2 mm thick) at different time points after injec-
tion. The accumulation of [111In]MWNT-Fab′ in the midbrain area
(sections c3–5) was clearly captured, with relatively lower radioac-
tivity detected in brain cortex compared to the central thalamic re-
gion. Fig. 3b are autoradiographs of brain slices from the mice
injected with [111In]EDTA containing an equivalent dose of radioac-
tivity. The results conﬁrmed that [111In]EDTA does not accumulate
in the brain. It should be noted that the exposure times for different
brains were slightly modiﬁed to achieve optimised image contrast
output, allowing direct comparison between slices from the sameFig. 4.Ramanmicroscopy ofMWNT-Fab′-DTPA inmouse brain. Ramanmicroscopy and clusteri
sections. Brain samples were from control mice ormice i.v. injectedwithMWNT-Fab′-DTPA (20
Clusters exhibiting similar Raman spectra are representedwith the same colour. The correspond
and G bands characteristic of MWNT could be only detected in treated capillaries but not in cobrain at one time point, but not directly between brains at different
time points.
To investigate further the heterogeneous brain distribution of
[111In]MWNT-Fab′, in situ brain perfusion was used which replaced
blood with physiological ringer perfusate containing [111In]MWNT-
Fab′. The perfusate is constantly supplied via the left cardiac ventricle
to themajor arteries supplying the head, with outﬂow via the descend-
ing vena cava and right atrium. This allows control of the [111In]MWNT-
Fab′ concentration reaching the brain which remains constant under
steady ﬂow conditions with no recirculation of the construct, and
bypasses clearance to peripheral organs such as liver. In this case, reduc-
tions in brain uptake over time can be reliably attributed to clearance
from the brain.
Accumulation of [111In]MWNT-Fab′ in different brain regions was
analysed by γ-counting at the end of a perfusion period of 5, 10 or
30 min. As shown in Fig. S9a, the radioactivity in different brain regions
increased when perfusion times increased from 5 min to 10 min. How-
ever, a reduction was detected when the perfusion lasted for 30 min.
One possibility is that the brain intake of f-MWNTs became saturated
after 10 min of steady administration so that no further entry to brain
was permitted; however in that case we would expect brain uptake at
30 min to be similar to uptake at 10 min. Another possibility is that
there is a clearance mechanism from the brain which equals or ex-
ceeds uptake after 10 min. The decreased radioactivity in different
brain regions detected at 30 min could be a result of both factors,
i.e., saturation of brain entry and a clearance mechanism. Fig. S9b
displays the % ID/g of tissue and no signiﬁcant differences were
observed between different brain regions at the same perfusion
time. The results correlate well with the SPECT images at 0–30 min
where the uptake of [111In]MWNT-Fab′ was more homogeneous
throughout the entire brain (Fig. 2).
SPECT/CT imaging and autoradiography addressed the brain up-
take of MWNT-Fab′-DTPA based on the detection of the radioisotope
bound to the nanotubes. Direct imaging of MWNT-Fab′-DTPA using
several state-of-art microscopic imaging techniques was further
conducted and documented below with the attempt to visualise
MWNT-Fab′-DTPA with greater spatial resolution in a label-free
manner.ng analysiswere performed onMWNT-Fab′-DTPA, isolated brain capillaries or whole brain
0 μg, 5min). Ramanmicroscopic images are shown in (a), generated using cluster analysis.
ing average Raman spectra for each of the clusters are shown in (b). Scale bars are 13 μm.D
ntrol capillaries, untreated or treated whole brain sections.
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The brain distribution of non-radiolabelled MWNT-Fab′-DTPA was
assessed directly by light microscopy and Raman spectroscopy. For
light microscopy, paraﬁnised brain sections were stained with Nissl &
Luxol Fast Blue (LFB) or Neutral Red. MWNT-Fab′-DTPA could be
visualised as small black clusters in different brain regions with no ab-
normality in brain structure observed (arrow heads, Fig. S10).
CNTs can be imaged in vivo due to their inherent optical properties by
Raman spectroscopy, NIR ﬂuorescence microscopy and photoacoustic
imaging [41–44]. In this study, Raman spectroscopy was employed to
image MWNT-Fab′-DTPA in the brain (Fig. 4). MWNT-Fab′-DTPA bulk
material (left panel) and samples of isolated brain capillaries (middle
panel) or whole brain sections from mice injected with MWNT-Fab′-
DTPA (right panel) were prepared along with samples from un-injected
mice as controls. Fig. 4a presents Raman microscopic images generated
using cluster analysis. Clusters exhibiting similar Raman spectra are pre-
sented in the same colour. The corresponding average Raman spectra
from different clusters are shown in Fig. 4b with the same colour codes.
The typical D (1309 cm−1) and G (1599 cm−1) bands, characteristic of
MWNTs, were clearly detected in the Raman spectra of MWNT-Fab′-
DTPA bulk material. In the isolated capillaries, 4 types of clusters
with different Raman spectra were identiﬁed. Clusters 1, 2 and 4
were related to tissue background as they were also detected in con-
trol capillaries in the absence of MWNT-Fab′-DTPA. Cluster 3,
exhibiting the typical D and G bands of MWNTs, was detected only
in brain capillaries from mice following i.v. MWNT-Fab′-DTPA treat-
ment. Due to sensitivity limitations of the technique, MWNT-Fab′-
DTPA could not be detected in whole brain sections, whose spectra
obtained were identical to those of control brains. This is expected
for two reasons; ﬁrst, MWNT-Fab′-DTPA achieved ~4 fold higher up-
take in capillaries compared with brain parenchyma; secondly, the
Raman microscope employed is of modest sensitivity and whole
brain sections were only 10 μm thick with less total tissue compared
to the capillary sample which was concentrated prior to imaging.
3.5. Multi-photon luminescence imaging and lifetime microscopy of
MWNT-Fab′-DTPA in whole brain slices
Multi-photon luminescence microscopy has been previously used to
image carbon materials in vivo [45] and two-photon photoluminescence
of SWNT has also been described [46]. In our recent study, the multi-
photon excitation property of f-MWNTs was investigated and imaging
parameters were optimised to visualise f-MWNTs in cells and paraﬁnised
tumour section after local administration [47]. The present study utilised
multi-photon excitation microscopy to image MWNT-Fab′-DTPA in
whole brain for the ﬁrst time. Mice were i.v. injected with MWNT-Fab′-
DTPA and perfused with DiI to stain blood vessels one hour later [28] at
sacriﬁce. 3D reconstructed images of brain slices are shown in Fig. 5a
and Movies S1 and S2. DiI-stained blood vessels are shown in red.
MWNT-Fab′-DTPA exhibited broad photoluminescence spectra
(λexcitation = 950 nm) so it could be imaged in blue, green and red chan-
nels, appearing white in the merged images. The corresponding maxi-
mum intensity projection images with signals detected from separate
channels are shown in Fig. S11. Lifetimemicroscopy was then performed
to distinguish the photoluminescence from MWNT-Fab′-DTPA and the
ﬂuorescence from DiI (Fig. 5b). Separate components of the overall
multiphoton-excited signals from physically-mixed DiI and MWNT-Fab
′-DTPA dispersion were differentiated using a convoluted Gaussian and
mono-exponential ﬁtting model:
Intensity tð Þ ¼ Offsetþ
Z
IRF t0ð Þ  PL t−t0ð Þ þ Fluorescence t−t0ð Þ½ dt0
where the instrument response function (IRF) is a normalised Gaussian
with a ﬁxed width (70 ps), the photoluminescence (PL) is Gaussianwith the same width as the IRF and Fluorescence is mono-exponential
decay. Intensity contribution from the DiI ﬂuorescence exponential
decay (displayed in red) and the MWNT-Fab′-DTPA photoluminescence
(shown in green) were clearly illustrated. The ﬂuorescence lifetimes of
DiI from position A were measured to be 1.18 ns, as shown in the decay
curve. The PL lifetime of the MWNT-Fab′ is too short to be accurately
measured by our instrument, limiting its value to 70 ps which is the
same as the IRF. The same imaging setting (λexcitation = 950 nm;
λemission = 600/40 nm) and lifetime analysis were applied to brain slices
frommice injectedwithMWNT-Fab′-DTPA andperfusedwithDiI. Signals
fromDiI andMWNT-Fab′-DTPA could be separated by their different life-
times. Brain capillaries were stained with DiI (red) and most of the
MWNT-Fab′-DTPA (green) was found to reside in blood vessels. Some
MWNT-Fab′-DTPA was observed distant from the vessels and appeared
to have translocated into brain parenchyma. The lifetime measurements
from DiI and MWNT-Fab′-DTPA in brain (points C and D) were in agree-
ment with the values obtained from their physical mixture. The lifetime
measurement from point E, where both MWNT-Fab′-DTPA and DiI was
present, resulted in a combination between a ﬂuorescence decay proﬁle
and a fast IRF component. When detecting emission at a lower wave-
length (460/60 nm) from the same ﬁeld of view, MWNT-Fab′-DTPA
could still be clearly detected due to its broad emission spectra. On the
other hand, DiI could not be captured in this region and the detected
signals were tissue autoﬂuorescence.
The phenomenon of the fast relaxation measured from MWNT-
Fab′-DTPA is expected as CNTs are known to possess very short PL
lifetimes [48], whereas DiI, being an organic ﬂuorophore, displayed
a longer ﬂuorescence lifetime N1 ns [49]. The distinct differences in
lifetimes of DiI and MWNT-Fab′-DTPA permit the distinction be-
tween DiI and MWNT-Fab′-DTPA signals. Individual lifetime images
of the two components were clearly resolved by lifetimemicroscopy,
providing evidence of the presence of MWNT-Fab′-DTPA in brain
tissues.
3.6. Transmission electron microscopy (TEM)
TEM is one of the best techniques at present to depict the mor-
phology of single, isolated MWNT and the surrounding biological
environment at the nanoscale level [50]. It was used to verify
MWNT-Fab′-DTPA brain parenchyma uptake. TEMwas ﬁrst conduct-
ed on isolated brain capillaries, showing the association of MWNT-
Fab′-DTPA with the brain microvasculature. Two brain capillaries
from control mice are shown in Fig. 6a, each with a single endothelial
cell forming the vessel wall and with one capillary containing a red
blood cell. Brain capillaries isolated from mice injected with
MWNT-Fab′-DTPA contained few clusters of MWNT-Fab′ (Fig. 6b),
observed residing on the luminal side of an endothelial cell (solid
and dashed rectangular insets, Fig. 6b1 & b2). MWNT-Fab′-DTPA
was also observed in whole brain sections (Fig. 6c, d, and the higher
magniﬁcation image in 6c1), probably in brain parenchyma as being
distant from a brain capillary (the lumen indicated as L at the edge of
Fig. 6c).
4. Conclusions
The kinetic distribution of 111In-labelled MWNT-Fab′-DTPA within
the brain environment was investigated in this study by quantitative
γ-scintigraphy, SPECT/CT imaging and autoradiography after i.v. injec-
tion in mice. The localization of MWNT-Fab′-DTPA with brain capil-
laries, demonstrated in vivo using γ-counting (Fig. 1c) and TEM
(Fig. 6), suggests that the entry of MWNTs into the brain occurs via its
endothelium. Signiﬁcant brain parenchyma to blood ratios during 1–
4 h after injection (Fig. 1d) indicate the ability of MWNT-Fab′-DTPA to
circumvent the BBB. Taking advantage of the intrinsic optical properties
of MWNT, MWNT-DTPA-Fab′ was imaged in brain in a label-free man-
ner by Raman microscopy and multi-photon luminescence microscopy
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Fig. 6. TEM studies of MWNT-Fab′-DTPA in whole brain sections and isolated brain capillaries. Electron micrographs of brain capillary extracts from (a) control mice; (b) MWNTs-Fab′-
DTPA injected mice. MWNT-Fab′-DTPA were observed in few images, illustrated in the solid and dashed rectangular insets to below b1 and b2. Electron micrographs of electron dense
MWNT-Fab′-DTPA were more readily observed in whole brain sections (c). An adjacent capillary was observed (L indicates the lumen of a capillary). The black rectangular inset
identifying MWNT-Fab′-DTPA clusters is shown in (c1) under a higher magniﬁcation and also with enhanced contrast (white dashed rectangular inset). (d) Is another example of
electron micrograph of MWNT-Fab′-DTPA observed in brain sections. Mice were i.v. injected with MWNT-Fab′-DTPA (200 μg) and were perfused with 0.1 M cacodylate buffer
containing 2.5% glutaraldehyde at 5 min after injection. The isolated brains were immersed in the perfusate for 24 h at 4 °C before further process for TEM imaging with detailed
methods described in the Materials and methods section.
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microscopy based on multi-photon excitation further conﬁrmed the
existence of MWNT-Fab′-DTPA in the brain. This study opens new
opportunities to use f-MWNT as a delivery system for therapeutic orFig. 5.Multi-photon luminescence imaging and lifetime microscopy of brain slices from mic
imaging of MWNT-Fab′-DTPA in brain slices (z-step: 1 μm, number of optical sections: 150;
appears in white; (b) lifetime microscopy of MWNT-Fab′-DTPA & DiI physical mixture, and M
ﬂuorescence intensity (grey), intensity contribution from long lifetimes (DiI, red), contri
measurements of positions A–E are displayed below the multiphoton images. A, C and B, D co
where both were present. Mice were i.v. injected with MWNT-Fab′-DTPA (200 μg) and brains
Brains were sectioned into 1 mm thick slices. Scale bar: 50 μm.diagnostic application to CNS. Studies using f-MWNT conjugated with
a brain targeting ligand is currently undertaking.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2015.12.039.e injected with MWNT-Fab′-DTPA. (a) 3D reconstruction of multi-photon luminescence
λexcitation = 950 nm). Blood vessels appear in red (Dil stained) while MWNT-Fab′-DTPA
WNT-Fab′-DTPA in brain slices by multi-photon excitation. From left: total multi-photon
bution from short lifetimes (MWNT-Fab′-DTPA, green), and merged image. Lifetime
rrespond to DiI and MWNT-Fab′-DTPA, respectively, while E corresponds to the position
were isolated at 1 h after injection. Mice were perfused with DiI and 4% PFA at sacriﬁce.
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